Global Tumor Necrosis Factor Inhibitors Drug Market Top Manufacturers, Latest Innovation with Trends pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
Continues to boost production capacity to meet increasing demand
Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions
95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination
Vaccines provide timely mass protection for adults aged 18 and above, including those over 60
TIANJIN, China, March 22, 2021 /PRNewswire/ CanSinoBIO Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). The approval is based on the vaccine s interim results for Phase III clinical trial and marks the first approval of Convidecia™ in an European Union member state.
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Chinese online pharmacy SPH gathers $159.7m in Series B round
Visual from Shanghai Pharmaceuticals website.
February 18, 2021
SPH Health Commerce, a Chinese Internet hospital and online pharmacy, has completed its Series B round of financing at 1.033 billion yuan ($159.7 million).
With this, the company will not be a controlled subsidiary of the country’s drug developer and distributor Shanghai Pharmaceuticals.
Shanghai-based SPH, which was founded in March 2015 by Shanghai Pharma, saw the stake held by the parent reduce to nearly 48% from 72.7% after the transaction, SPH announced in a statement on Thursday.
The billion-yuan investment was completed on January 18. As a result of the new financing, Hong Kong and Shanghai-listed Shanghai Pharma will no longer consolidate the financials of SPH into its financial statements.